澳大新語 • 2021 UMAGAZINE 24 31 專題探討 • TOPIC INSIGHT partners to create such standards and to make them internationally recognised.’ He adds that his laboratory has established joint laboratories with all three regulatory bodies in the US, Europe, and China, namely the United States Pharmacopoeia Convention (USPC), the European Pharmacopoeia Commission (Ph. Eur. Commission), and the Chinese National Institutes for Food and Drug Control. The joint laboratories focus on creating standards for the USP, the Ph. Eur., and the ChP. Standards for Chinese Herbs in the USP A pharmacopoeia is a legally binding collection of standards and specifications for medicines. Not only is the USP document considered a national standard for drugs and dietary supplements in the US, it is also used in over 140 countries and regions in the world. In 2012, the SKL‑QRCM signed an agreement with the USPC to establish a joint laboratory that tackles challenges in the development of international quality standards for Chinese medicines, making UM the first higher education institution to establish a joint laboratory with USPC. Both institutions have researched and established standards for Panax notoginseng (Sanqi), Lycium barbarum (Goji), Cordyceps militaris, powders of fermented Cordyceps sinensis, Galangal, Dendrobium officinale, Pogostemon cablin, Gastrodia elata, and other herbs. The USP currently contains the standards for 42 Chinese medicinal herbs. SKL-QRCM Deputy Director Li Shaoping, who is a Distinguished Professor at UM’s Institute of Chinese Medical Sciences (ICMS), specialises in quality control and active ingredient research. As a world-renowned scholar in pharmaceutical analysis, Prof Li has served on the Herbal Medicines Compendium – East Asia Expert Panel of the USPC since 2021. Prof Li has entered the list of the top 100 analytical scientists in the world for two consecutive years since 2020. He is also the 2021年5月，珠海澳大科技研究院的中華醫藥及轉化 醫學研發中心正式揭牌，標誌著澳大將通過中心推進 大學的科技創新、澳門產業多元化，以及粵港澳大灣 區國際科技創新中心的發展。王教授表示，中藥質量 研究國家實驗室和澳門中藥研發中心正與入駐澳門 的藥企一道，努力踐行澳門特別行政區行政長官賀一 誠對澳大師生的囑託：充分發揮國家重點實驗室的引 領作用，聚焦以中醫藥研發製造為切入點的大健康產 業、高新技術產業等重點產業，完善產學研深度融合 機制，走出一條澳大科研成果產業化的道路。 The University of Macau (UM) is a firm supporter of the Chinese medicine industry, a sector essential to the moderate diversification of Macao’s economy. UM is home to the State Key Laboratory of Quality Research in Chinese Medicine (SKL‑QRCM), China’s first‑ever state key laboratory in Chinese medicine. Over the years, the laboratory has made impressive progress in forging business partnerships, nurturing talent, creating platforms for international cooperation, and pushing forward the standardisation and internationalisation of Chinese medicine. Moreover, the laboratory has established quality standards for a dozen Chinese medicinal plants for authoritative publications such as European Pharmacopoeia (Ph. Eur.), United States Pharmacopeia (USP), and Chinese Pharmacopoeia (ChP), in order to create favourable conditions for Chinese medicine to succeed in the international market. Promoting Chinese Medicine on the World Stage In 2019, the Central Committee of the Communist Party of China and the State Council unveiled the Outline of the Development Plan for the Guangdong‑Hong Kong‑Macao Greater Bay Area. The document pledges support for Macao to leverage the advantages of the SKL‑QRCM, to establish an internationally recognised reference standard for Chinese medicine products, and to promote the standardisation and internationalisation of Chinese medicine. SKL‑QRCM Director Prof Wang Yitao, who joined UM in 2002, is committed to the modernisation, commercialisation, and internationalisation of Chinese medicine. ‘For Chinese medicine to go global, it is necessary to establish internationally recognised quality standards,’ says Prof Wang. ‘At UM, we are working with domestic and overseas
RkJQdWJsaXNoZXIy MTQ1NDU2Ng==